Clinical Trial

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of 24 months and a maximum follow-up time of 36 months, at the significance level of 0.1, to achieve the power of 0.8, the sample size needed is 24 patients and the number of events required is 17. These results are based on a one-sided test with exponential assumption for survival time.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-10.
Trial Details
NCT Number NCT07470489
Lead Sponsor M.D. Anderson Cancer Center
Conditions Anaplastic Thyroid Cancer
Enrollment 12 participants
Start Date 2026-09-30
Primary Completion 2030-09-01 (estimated)
Study Completion 2032-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29